Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in rotator cuff tendinopathy
NCT05758415Phase 3Terminated
- Sponsor
- Novartis
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in rotator cuff tendinopathy (RCT) comparing Secukinumab with Placebo (2 arms). Primary endpoint: Western Ontario Rotator Cuff Index Physical Symptom Domain at 16 weeks. Started Aug 2023; status: terminated.
02
Drugs
secukinumab
03
Conditions
rotator cuff tendinopathy (RCT)
Beyond the preview
Go deeper on NCT05758415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05758415.